Activated Partial Thromboplastin Time (aPTT)
The activated partial thromboplastin time (aPTT) is the standard serum test used to monitor therapeutic unfractionated heparin therapy, with a target range of 1.5 to 2.5 times the control value (or 60-85 seconds in pediatrics). 1
Primary Monitoring Approach
The FDA-approved labeling explicitly states that dosage is considered adequate when the aPTT is 1.5 to 2 times normal 1. This recommendation is supported by the American College of Chest Physicians guidelines, which confirm that aPTT is the usual monitoring test for therapeutic-dose heparin 2.
Monitoring Schedule
- Continuous IV infusion: Check aPTT at baseline, then approximately every 4 hours initially, then at appropriate intervals once therapeutic 1
- Intermittent IV injection: Perform coagulation tests before each injection during initiation, then at appropriate intervals 1
- Subcutaneous injection: Draw samples 4-6 hours after injection for optimal assessment 1
Alternative: Anti-Factor Xa Assay
Use anti-Xa monitoring (target 0.3-0.7 units/mL) in patients requiring unusually high heparin doses (≥35,000 units/day) or demonstrating "heparin resistance." 2 The guidelines specifically note that patients randomized to anti-Xa-based dosing achieved similar clinical outcomes with lower heparin doses compared to aPTT-based dosing in this population 2.
When to Consider Anti-Xa Over aPTT
- Patients requiring very high heparin doses to achieve therapeutic aPTT
- Suspected heparin resistance
- Presence of lupus anticoagulants or other aPTT-interfering factors
- Acute phase reactants or consumptive coagulopathies 3
Recent evidence suggests anti-Xa may offer advantages including faster time to therapeutic levels and more consistent anticoagulation 4, 3, though the guidelines note that anti-Xa assays also vary in their responsiveness to heparin, making standardization problematic 2.
Special Situations
For cardiovascular surgery with cardiopulmonary bypass, use activated clotting time (ACT) instead of aPTT to monitor the much higher heparin doses used in this setting 2.
Critical Safety Monitoring
Beyond anticoagulation monitoring, periodically check platelet counts, hematocrit, and stool occult blood throughout therapy regardless of route 1. This detects heparin-induced thrombocytopenia (HIT) and bleeding complications early.
Important Caveats
The therapeutic aPTT range of 1.5-2.5 times control is based on weak evidence from a single 1970s retrospective study and has never been validated in randomized trials 2. Additionally, aPTT results vary significantly between reagents and coagulometers—the same heparin concentration can produce aPTT ratios ranging from 1.6-2.7 to 3.7-6.2 depending on the laboratory system used 2. Each institution should calibrate its therapeutic aPTT range to its specific reagent and coagulometer 2.